Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun pharmacology An anti-retroviral prodrug of the
protease inhibitor amprenavir . It is used to treatHIV infected patients.
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word fosamprenavir.
Examples
-
Significant interactions were observed between telaprevir and boosted-lopinavir, darunavir and fosamprenavir, such that telaprevir-based combination therapy is not currently being evaluated for people taking these HIV medicines.
unknown title 2011
-
The ritonavir-boosted protease inhibitors studied were lopinavir, atazanavir, darunavir and fosamprenavir; the NNRTI was efavirenz and the NRTI was tenofovir.
unknown title 2011
-
HIV treatment regimens containing the protease inhibitor (PI) LEXIVA® (fosamprenavir calcium) dosed ...
THE MEDICAL NEWS Editors 2010
-
INTELENCE should not be coadministered with the following ARVs: tipranavir/ritonavir, fosamprenavir/ritonavir, atazanavir/ritonavir, full-dose ritonavir (600 mg bid), protease inhibitors administered without low-dose ritonavir, and other NNRTIs
unknown title 2009
-
HIV treatment regimens containing the protease inhibitor (PI) LEXIVA® (fosamprenavir calcium) dosed ...
THE MEDICAL NEWS 2009
-
There is no reason to suspect decreased susceptibility, thus the dose of LPV / r is higher than currently recommended in a patient concomitantly on fosamprenavir (FPV).
JAMA current issue 2009
-
There is no reason to suspect decreased susceptibility, thus the dose of LPV / r is higher than currently recommended in a patient concomitantly on fosamprenavir (FPV).
JAMA current issue 2009
-
INTELENCE should not be coadministered with the following ARVs: tipranavir/ritonavir, fosamprenavir/ritonavir, atazanavir/ritonavir, full-dose ritonavir (600 mg bid), protease inhibitors administered without low-dose ritonavir, and other NNRTIs
unknown title 2009
-
Information includes initial recommendations for the new PIs lopinavir / ritonavir, atazanavir, and fosamprenavir, and updated recommendations for other dual PI regimens and NNRTIs.
JAMA current issue 2009
-
Information includes initial recommendations for the new PIs lopinavir / ritonavir, atazanavir, and fosamprenavir, and updated recommendations for other dual PI regimens and NNRTIs.
JAMA current issue 2009
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.